Skip to content

Use of the oral sialogogue, oryza tablet, in reducing drug-induced xerostomia in patients with overactive bladder or neurogenic bladder: randomized clinical study

Use of the oral sialogogue (Oryza tablet) in reducing drug-induced xerostomia in patients with overactive bladder or neurogenic bladder: randomized clinical study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240715015
Enrollment
32
Registered
2024-07-15
Start date
2021-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xerostomia in patients with overactive &amp

Interventions

Anthocyanins extracted from Oryza sativa was produced in topical tablet form for relieving xerostomia symptoms,Placebo arm
Active Comparator Drug,Placebo Comparator Drug
Topical sialogogue,Placebo

Sponsors

Faculty of medicine Ramathibodi Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Overactive bladder and neurogenic bladder patient who use anticholinergic drug with xerostomia symptoms Age 18 year old or older Informed consent was made

Exclusion criteria

Exclusion criteria: Recently xerostomia symptoms within 3 months History of head & neck radiation Autoimmune disease History of salivary gland surgery Dental and oral infection Uncooperative patient History of drug allergy

Design outcomes

Primary

MeasureTime frame
Xerostomia symptoms 1 month Subjective dry mouth VAS

Secondary

MeasureTime frame
Stimulated salivary flow rate 1 month Prohibited from eating and drinking for 60 mins before saliva collection. They chewed a paraffin cube for 30 seconds, then spit into a tube for 5 mis, after which the saliva volume was measured.

Countries

Thailand

Contacts

Public ContactSurawach Piyawannarat

Faculty of medicine Ramathibodi Hospital, Mahidol University

surawach.p@gmail.com0853256325

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026